Gene transfer to, and expression in, neurons in vivo: We have been developing HSV as a vector for gene transfer to the nervous system using a mouse model of a human lysosomal disease. Specifically, we have used a ?-glucuronidase (GUSB) negative mouse (gusmps/gusmps), with mucopolysaccharidosis (MPS) type VII (Sly disease), as an animal model. We have overcome the problem of viral toxicity in the CNS by using ICP34.5 deletion mutants (the deletion used in HSV for human cancer therapy trials) and studied the spread of, and expression from, vector genomes following inoculation at various locations in the CNS. Using the MPS VII mouse model, the long-term level of GUSB expression was found to be within the range required to correct disease. In the present application we wish to extend the utility of HSV virus vectors by developing an expression cassette utilizing the LAT promoter and the LAT gene chromatin boundaries from HSV. These elements give the LAT gene its long term expression characteristics and make it so desirable for vector expression. This cassette will enable long-term expression from our HSV vector to be improved. It will be engineered into another viral vector, to determine whether all the elements for long-term stable expression in the HSV vector are contained within the cassette. We will also answer a basic question about our HSV vector: does it need to replicate in order spread efficiently through the nervous system? The goal of our studies is to address the problem of treatment of the global lesions in neurogenetic diseases by developing a method to distribute a vector genome widely in the nervous system in vivo, using a ubiquitous human virus. These studies also provide a model for studying gene regulation in neuronal cells in vivo using state of the art techniques of molecular biology.

Public Health Relevance

Developmental neurogenetic diseases can only be studied, and potentially treated, once systems to predictably deliver and express genes in neuronal cells are developed. We have utilized herpes simplex virus (HSV) as a vector for expressing genes in neuronal cells. This human DNA virus, for which about 90% of the U.S. population is seropositive, forms latent infections in neurons which persist for the lifetime of the individual. Using HSV derived vectors, we will study the nervous system component of lysosomal storage diseases. Lysosomal storage in neurons results in severe mental retardation in most children with these diseases.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Clinical Neuroimmunology and Brain Tumors Study Section (CNBT)
Program Officer
Tagle, Danilo A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Schools of Medicine
United States
Zip Code
Liu, Wenpei; Griffin, Gerald; Clarke, Trena et al. (2015) Bilateral single-site intracerebral injection of a nonpathogenic herpes simplex virus-1 vector decreases anxiogenic behavior in MPS VII mice. Mol Ther Methods Clin Dev 2:14059
Volcy, Ketna; Fraser, Nigel W (2013) DNA damage promotes herpes simplex virus-1 protein expression in a neuroblastoma cell line. J Neurovirol 19:57-64
Simonato, Michele; Bennett, Jean; Boulis, Nicholas M et al. (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9:277-91
Husain, T; Passini, M A; Parente, M K et al. (2009) Long-term AAV vector gene and protein expression in mouse brain from a small pan-cellular promoter is similar to neural cell promoters. Gene Ther 16:927-32
Wolfe, John H (2009) Gene therapy in large animal models of human genetic diseases. Introduction. ILAR J 50:107-11
Berges, Bradford K; Wolfe, John H; Fraser, Nigel W (2007) Transduction of brain by herpes simplex virus vectors. Mol Ther 15:20-9
Berges, Bradford K; Yellayi, Srikanth; Karolewski, Brian A et al. (2006) Widespread correction of lysosomal storage in the mucopolysaccharidosis type VII mouse brain with a herpes simplex virus type 1 vector expressing beta-glucuronidase. Mol Ther 13:859-69
Berges, B K; Wolfe, J H; Fraser, N W (2005) Stable levels of long-term transgene expression driven by the latency-associated transcript promoter in a herpes simplex virus type 1 vector. Mol Ther 12:1111-9
Kang, Wen; Mukerjee, Ruma; Fraser, Nigel W (2003) Establishment and maintenance of HSV latent infection is mediated through correct splicing of the LAT primary transcript. Virology 312:233-44
Heuer, Gregory G; Passini, Marco A; Jiang, Kanli et al. (2002) Selective neurodegeneration in murine mucopolysaccharidosis VII is progressive and reversible. Ann Neurol 52:762-70

Showing the most recent 10 out of 25 publications